Tevogen director granted 75,000 restricted shares

A Tevogen Inc. director received a 75,000-share restricted stock grant that vests over three years, increasing direct holdings to 123,678 shares.

Rhea-AI Filing Summary

Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. Goh Keow Lin reported acquisition or exercise transactions in this Form 4 filing.

Tevogen Inc. (TVGN) reported that director Goh Keow Lin received a grant of 75,000 shares of restricted common stock on September 11, 2026 under the Tevogen Inc. 2024 Omnibus Incentive Plan. The award vests in three equal annual installments starting September 11, 2027, conditional on continued service, bringing the director’s direct holdings to 123,678 shares.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Goh Keow Lin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	75,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 123,678 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.

Key Figures

Restricted stock granted: 75,000 shares Per-share grant price: $0.00 per share Holdings after transaction: 123,678 shares +1 more

4 metrics

Restricted stock granted 75,000 shares Grant of restricted common stock to director on September 11, 2026

Per-share grant price $0.00 per share Compensation-related grant under 2024 Omnibus Incentive Plan

Holdings after transaction 123,678 shares Total direct common stock holdings reported after the grant

Vesting installments 3 equal annual installments Restricted stock vests ratably, starting September 11, 2027

Key Terms

restricted stock, 2024 Omnibus Incentive Plan, vest ratably

3 terms

restricted stock financial

"Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Omnibus Incentive Plan financial

"under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest"

vest ratably financial

"which will vest ratably in three equal annual installments commencing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tevogen Inc. (TVGN) report for Goh Keow Lin?

Tevogen Inc. reported that director Goh Keow Lin received a grant of 75,000 shares of restricted common stock on September 11, 2026. The transaction is classified as a grant or award acquisition with no purchase price per share reported.

How many Tevogen Inc. (TVGN) shares does Goh Keow Lin hold after this Form 4 transaction?

Following the restricted stock grant, director Goh Keow Lin is reported to hold 123,678 shares of Tevogen Inc. common stock directly. This total includes the newly granted 75,000 restricted shares subject to vesting conditions.

What is the vesting schedule for the 75,000 restricted Tevogen Inc. (TVGN) shares?

The 75,000 restricted shares granted to Goh Keow Lin vest ratably in three equal annual installments, beginning on September 11, 2027. Vesting is conditioned on the director remaining in service with Tevogen Inc. on each applicable vesting date.

Did Tevogen Inc.’s Form 4 indicate a purchase price for the 75,000-share grant?

The filing reports a per-share price of $0.00 for the 75,000 restricted shares. This reflects that the transaction is a compensation-related grant under the company’s 2024 Omnibus Incentive Plan rather than an open-market purchase.

Was the Tevogen Inc. (TVGN) restricted stock grant made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not affirmed, and the footnote describes the award simply as a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, with no reference to a trading plan.

What role does Goh Keow Lin hold at Tevogen Inc. (TVGN) in this Form 4?

In this Form 4, Goh Keow Lin is identified as a director of Tevogen Inc. The reported 75,000-share restricted stock grant represents equity-based compensation associated with that board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 08:08 PM Accepted by SEC EDGAR 09/15/2026 - 08:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goh Keow Lin

(Last) (First) (Middle)

C/O TEVOGEN BIO HOLDINGS INC.

15 INDEPENDENCE BLVD, STE 410

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tevogen Inc. [ TVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A		75,000(1)	A	$0.00	123,678	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.

	/s/ Kirti Desai, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)